A longitudinal trial comparing chloroquine as monotherapy or in combination with artesunate, azithromycin or atovaquone-proguanil to treat malaria

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Laufer, Miriam K ^a   Thesing, Phillip C ^a   Dzinjalamala, Fraction K ^b   Nyirenda, Osward M ^b   Masonga, Rhoda ^b   Laurens, Matthew B ^a   Stokes Riner, Abbie ^c   Taylor, Terrie E ^d   Plowe, Christopher V ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b UNIVERSITY OF MALAWI   (Malawi)

^c EMMES CORPORATION   (United States)

^d MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTESUNATE; ATOVAQUONE PLUS PROGUANIL; AZITHROMYCIN; CHLOROQUINE; HEMOGLOBIN;

ANEMIA; ANTIMALARIAL DRUG RESISTANCE; ARTICLE; CHILD; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEALTH CARE FACILITY; HEMOGLOBIN DETERMINATION; HUMAN; INCIDENCE; INFANT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALARIA; MALAWI; MALE; MARKER GENE; MIXED INFECTION; MONOTHERAPY; NONHUMAN; OPEN STUDY; PFCRT GENE; PRURITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME;

ANTIMALARIALS; ARTEMISININS; ATOVAQUONE; AZITHROMYCIN; CHILD, PRESCHOOL; CHLOROQUINE; DRUG COMBINATIONS; DRUG RESISTANCE; ENDPOINT DETERMINATION; FEMALE; GENOTYPING TECHNIQUES; HUMANS; INFANT; LONGITUDINAL STUDIES; MALARIA; MALE; PROGUANIL;

EID: 84865095149     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042284     Document Type: Article

References (21)

1. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, et al. (2008) Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 359: 2619-2620.
2. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, et al. (2009) Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361: 455-467.
3. Kublin JG, Cortese JF, Njunju EM, Mukadam RA, Wirima JJ, et al. (2003) Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J Infect Dis 187: 1870-1875.
4. Laufer MK, Thesing PC, Eddington ND, Masonga R, Dzinjalamala FK, et al. (2006) Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med 355: 1959-1966.
5. Frosch AE, Venkatesan M, Laufer MK, (2011) Patterns of chloroquine use and resistance in sub-Saharan Africa: a systematic review of household survey and molecular data. Malar J 10: 116.
6. World Health Organization (2001) Antimalarial drug combination therapy: Report of a WHO technical consultation. Geneva: World Health Organization, 36 p.
7. Nyunt MM, Plowe CV, (2007) Pharmacologic advances in the global control and treatment of malaria: combination therapy and resistance. Clin Pharmacol Ther 82: 601-605.
8. Teja-Isavadharm P, Watt G, Eamsila C, Jongsakul K, Li Q, et al. (2001) Comparative pharmacokinetics and effect kinetics of orally administered artesunate in healthy volunteers and patients with uncomplicated falciparum malaria. Am J Trop Med Hyg 65: 717-721.
9. Suputtamongkol Y, Newton PN, Angus B, Teja-Isavadharm P, Keeratithakul D, et al. (2001) A comparison of oral artesunate and artemether antimalarial bioactivities in acute falciparum malaria. Br J Clin Pharmacol 52: 655-661.
10. Zhang SQ, Hai TN, Ilett KF, Huong DX, Davis TM, et al. (2001) Multiple dose study of interactions between artesunate and artemisinin in healthy volunteers. Br J Clin Pharmacol 52: 377-385.
11. Di Paolo A, Barbar C, Chella A, Angeletti CA, Del Tacca M, (2002) Pharmacokinetics of azithromycin in lung tissue, bronchial washing, and plasma in patients given multiple oral doses of 500 and 1000 mg daily. Pharmacol Res 46: 545-550.
12. Lefevre G, Looareesuwan S, Treeprasertsuk S, Krudsood S, Silachamroon U, et al. (2001) A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg 64: 247-256.
13. Sabchareon A Attanath P, Phanuaksook P, Chanthavanich P, Poonpanich Y, et al. (1998) Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg 92: 201-206.
14. Butcher GA, Sinden RE, (2003) Persistence of atovaquone in human sera following treatment: inhibition of Plasmodium falciparum development in vivo and in vitro. Am J Trop Med Hyg 68: 111-114.
15. Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, et al. (2001) A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med 344: 257-263.
16. Plowe CV, (2005) Antimalarial drug resistance in Africa: strategies for monitoring and deterrence. Curr Top Microbiol Immunol 295: 55-79.
17. Quinto L, Aponte JJ, Sacarlal J, Espasa M, Aide P, et al. (2006) Haematological and biochemical indices in young African children: in search of reference intervals. Trop Med Int Health 11: 1741-1748.
18. World Health Organization (2003) Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated faliciparum malaria. Geneva: World Health Organization, 68 p.
19. Cattamanchi A, Kyabayinze D, Hubbard A, Rosenthal PJ, Dorsey G, (2003) Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp. Am J Trop Med Hyg 68: 133-139.
20. Ademowo OG, Sodeinde O, Walker O, (2000) The disposition of chloroquine and its main metabolite desethylchloroquine in volunteers with and without chloroquine-induced pruritus: evidence for decreased chloroquine metabolism in volunteers with pruritus. Clin Pharmacol Ther 67: 237-241.
21. Onyeji CO, Ogunbona FA, (2001) Pharmacokinetic aspects of chloroquine-induced pruritus: influence of dose and evidence for varied extent of metabolism of the drug. Eur J Pharm Sci 13: 195-201.